I promise

"I promise, Suzy... Even if it takes the rest of my life." - Nancy G. Brinker, founder of Susan G. Komen for the Cure

What is Triple Negative Breast Cancer?


Just in recent years, Triple Negative Breast Cancer has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" type of cancer. Being Triple Negative, you don't have a targeted therapy and that your only treatment option is chemotherapy.

Triple Negative is seen in about 15% of all breast cancers. Triple Negative is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TN is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Carpe diem

Seize Each new Day with Renewed Strength,
Believe in Yourself, Go forward with
Courage and faith
to face whatever Tomorrow may bring.

Chicks For Charity motto:

Enjoy life. Laugh a lot.
Work hard. Play hard.
Be thankful for our blessings.
Share the wisdom. Give back

Saturday, April 27, 2013

Bio-Path's Plan to Develop Liposomal Grb-2 as a Targeted Therapy Against Inflammatory Breast Cancer and Triple Negative Breast Cancer

"...Focusing on its longer-term pipeline, the Company announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path’s plan is to develop Liposomal Grb-2 as a targeted therapy against TNBC and IBC. Treatment goals are two-pronged: the first being to develop Liposomal Grb-2 as a tumor reduction agent in combination with other approved drugs in pre-operative settings, and the second is to develop Liposomal Grb-2 as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients. Both of these treatment goals address high need situations for patients..."

UPDATE July 22, 2013- "It is expected that after the completion of pre-clinical studies, a Phase I clinical trial in TNBC and IBC will be initiated by Bio- Path Holdings Inc. in 2014."
http://bionews-tx.com/news/2013/07/22/bio-path-holdings-initiates-development-of-liposomal-grb-2-for-triple-negative-and-inflammatory-breast-cancers/ (Click link to story)

http://www.rxir.com/SSI/ClientPR/201324102455.shtml (Link to story)

http://bionews-tx.com/news/2013/04/04/bio-path-holdings-expands-reach-of-non-toxic-md-anderson-tested-cancer-treatment/ (Link to story)

http://finance.yahoo.com/news/bio-path-shares-attractive-now-153340813.html (Link to story)

http://seekingalpha.com/instablog/685353-grant-zeng/1572271-bio-path-shares-are-attractive-now (Link to story)

1 comment:

  1. Thanks for sharing this. Hopefully it will be a breakthrough in two real tough cancers.


Note: Only a member of this blog may post a comment.

Total Pageviews

Click to help fund mammograms for the uninsured

The Breast Cancer Site

Click to join me in support group

Inspire health and wellness support groups

Triple Negative Breast Cancer Foundation

Triple Negative Breast Cancer Foundation
"click image to link"

"Click image to link"

The SCAR Project

The SCAR Project
"Click image to link"


"Click image to link"

Breast Cancer Awareness Body Painting Project

Breast Cancer Awareness Body Painting Project
"Click image to link"